Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Alok Chandra, Ravi Kanth, Sandeep Thareja Department of Gastroenterology, Base Hospital, New Delhi, IndiaCorrespondence: Ravi KanthDepartment of Gastroenterology, Base Hospital, New Delhi, IndiaEmail ravikanthf2@gmail.comBackground: Adalimumab (ADA) is approved for the management of lcerative coliti...

Full description

Saved in:
Bibliographic Details
Main Authors: Chandra A, Kanth R, Thareja S
Format: article
Language:EN
Published: Dove Medical Press 2019
Subjects:
ulcerative colitis
steroid refractory
adalimumab
biosimilar
exemptia
Medicine (General)
R5-920
Online Access:https://doaj.org/article/4ee0ed2fcfae45939725130e128f6ee8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/4ee0ed2fcfae45939725130e128f6ee8

Similar Items